RT Journal Article
SR Electronic
T1 International Expert-Based Consensus Definition, Staging Criteria, and Minimum Data Elements for Osteoradionecrosis of the Jaw: An Inter-Disciplinary Modified Delphi Study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.04.07.24305400
DO 10.1101/2024.04.07.24305400
A1 ,
A1 Moreno, Amy C.
A1 Watson, Erin E.
A1 Humbert-Vidan, Laia
A1 Peterson, Douglas E.
A1 van Dijk, Lisanne V
A1 Urbano, Teresa Guerrero
A1 Van den Bosch, Lisa
A1 Hope, Andrew J.
A1 Katz, Matthew S.
A1 Hoebers, Frank J.P.
A1 Aponte Wesson, Ruth A.
A1 Bates, James E.
A1 Bossi, Paolo
A1 Dayo, Adeyinka F.
A1 Doré, Mélanie
A1 Fregnani, Eduardo Rodrigues
A1 Galloway, Thomas J.
A1 Gelblum, Daphna Y.
A1 Hanna, Issa A.
A1 Henson, Christina E.
A1 Kiat-amnuay, Sudarat
A1 Korfage, Anke
A1 Lee, Nancy Y.
A1 Lewis, Carol M.
A1 Lynggaard, Charlotte Duch
A1 Mäkitie, Antti A.
A1 Magalhaes, Marco
A1 Mowery, Yvonne M.
A1 Muñoz-Montplet, Carles
A1 Myers, Jeffrey N.
A1 Orlandi, Ester
A1 Patel, Jaymit
A1 Rigert, Jillian M.
A1 Saunders, Deborah
A1 Schoenfeld, Jonathan D.
A1 Selek, Ugur
A1 Somay, Efsun
A1 Takiar, Vinita
A1 Thariat, Juliette
A1 Verduijn, Gerda M.
A1 Villa, Alessandro
A1 West, Nick
A1 Witjes, Max J.H.
A1 Won, Alex
A1 Wong, Mark E.
A1 Yao, Christopher M.K.L.
A1 Young, Simon W.
A1 Al-eryani, Kamal
A1 Barbon, Carly E.A.
A1 Buurman, Doke J.M.
A1 Dieleman, François J.
A1 Hofstede, Theresa M.
A1 Khan, Abdul Ahad
A1 Otun, Adegbenga O.
A1 Robinson, John C.
A1 Hum, Lauren
A1 Johansen, Jorgen
A1 Lalla, Rajesh
A1 Lin, Alexander
A1 Patel, Vinod
A1 Shaw, Richard J.
A1 Chambers, Mark S.
A1 Ma, Daniel
A1 Singh, Mabi
A1 Yarom, Noam
A1 Mohamed, Abdallah Sherif Radwan
A1 Hutcheson, Katherine A.
A1 Lai, Stephen Y.
A1 Fuller, Clifton David
YR 2024
UL http://medrxiv.org/content/early/2024/04/09/2024.04.07.24305400.abstract
AB Purpose Osteoradionecrosis of the jaw (ORNJ) is a severe iatrogenic disease characterized by bone death after radiation therapy (RT) to the head and neck. With over 9 published definitions and at least 16 diagnostic/staging systems, the true incidence and severity of ORNJ are obscured by lack of a standard for disease definition and severity assessment, leading to inaccurate estimation of incidence, reporting ambiguity, and likely under-diagnosis worldwide. This study aimed to achieve consensus on an explicit definition and phenotype of ORNJ and related precursor states through data standardization to facilitate effective diagnosis, monitoring, and multidisciplinary management of ORNJ.Methods The ORAL Consortium comprised 69 international experts, including representatives from medical, surgical, radiation oncology, and oral/dental disciplines. Using a web-based modified Delphi technique, panelists classified descriptive cases using existing staging systems, reviewed systems for feature extraction and specification, and iteratively classified cases based on clinical/imaging feature combinations.Results The Consortium ORNJ definition was developed in alignment with SNOMED-CT terminology and recent ISOO-MASCC-ASCO guideline recommendations. Case review using existing ORNJ staging systems showed high rates of inability to classify (up to 76%). Ten consensus statements and nine minimum data elements (MDEs) were outlined for prospective collection and classification of precursor/ORNJ stages.Conclusion This study provides an international, consensus-based definition and MDE foundation for standardized ORNJ reporting in cancer survivors treated with RT. Head and neck surgeons, radiation, surgical, medical oncologists, and dental specialists should adopt MDEs to enable scalable health information exchange and analytics. Work is underway to develop both a human- and machine-readable knowledge representation for ORNJ (i.e., ontology) and multidisciplinary resources for dissemination to improve ORNJ reporting in academic and community practice settings.Competing Interest StatementThe individual collaborators/authors declare the following competing interests: National Institutes of Health (grants, travel, honoraria); Padagis (honoraria); NPi (honoraria); Castle Biosciences (consulting); Galera Therapeutics (consulting, grants); EMD Serono (advisory board, in-kind support, consulting, grants); UpToDate Inc (royalties); Cardinal Health (grants, consulting); Guy's and St Thomas' NHS Foundation Trust (grants); King's College London (grants); Canadian Institutes of Health Research (grants); Canadian Foundation for Innovation (grants);Cancer Research Society (grants); Merck (advisory service, consulting, honoraria, travel, grants); Pfizer (stock, consulting, honoraria). Moderna (stock); Healthcare Services Group (stock); Dr. Reddy's Laboratories (stock); CVS Health (stock). Organon (stock); Myomo (stock); Rewalk Robotics (stock); Elekta AB (grants, in-kind support, honoraria, travel); Philips Medical System (honoraria, travel); Varian/Siemens Healthineers (honoraria, travel). Kallsio, Inc. (royalties, licenses);Nanobiotix (consulting); LEO SAB (consulting, stock options);Shanghai JoAnn Medical Company(consulting); Yingming (consulting); Sanofi-Regeneron (honoraria); Merck Sharp & Dohme (honoraria); Glaxo Smith Kline (honoraria); Merus (honoraria); Sun Pharma (honoraria); Angelini (honoraria, consulting); MeiraGtx (grants);PCCA (grants); Mureva (grants); K pharmaceuticals (honoraria, consulting); Lipella Pharmaceuticals (honoraria, consulting); Amgen (honoraria, consulting); Bristol Myers Squibb (grants); Debiopharm (grants);ACI Clinical (consulting);Genentech (consulting); Astellas (consulting); Immunitas (consulting, stock);SIRPant (consulting); LEK (consulting); Burns and White (expert testimony); Doximity (stock).Funding StatementThis work was supported directly or in part by funding/resources from the National Institutes of Health (NIH) National Institute for Dental and Craniofacial Research (K01DE030524, U01DE032168, R21DE031082, R56/R01DE025248, R01DE028290); NIH National Cancer Institute (K12CA088084, P30CA016672); the NIH National Institute of Biomedical Imaging and Bioengineering (R25EB025787); the University of Texas MD Anderson Cancer Center via the Charles and Daneen Stiefel Center for Head and Neck Cancer Oropharyngeal Cancer Research Program; and the MD Anderson Image-guided Cancer Therapy Program.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB of the University of Texas MD Anderson Cancer Center gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesData availability statement: The data that support the findings of this study are openly available in an NIH-supported generalist scientific data repository [figshare] at http://doi.org/10.6084/m9.figshare.25546723; though embargoed pending peer-review, data is available upon request in the interim. http://doi.org/10.6084/m9.figshare.25546723